SCHEMBL4383311

SCHEMBL4383311

CCc1cc(Br)cnc1-c1ccc(Br)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.40
RAB9A P51151 5/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
NPC1 O15118 3/20 0.36
NFKB1 P19838 2/20 0.36
NFKB2 Q00653 2/20 0.36
RELA Q04206 2/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.35
TP53 P04637 1/20 0.35
CA2 P00918 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 2/20 0.33
HTT P42858 1/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP1B1 Q16678 1/20 0.33
SPR P35270 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4383313 0.82 NPC1 (0.42) RAB9ASMN1; SMN2NPC1L3MBTL1GAA
SCHEMBL4394090 0.79 NPC1 (0.35) GBA1NPC1MAPK1GAACA2
SCHEMBL4383276 0.77 S1PR1 (0.37) GBA1RAB9ASMN1; SMN2NPC1NFKB1
SCHEMBL4386588 0.76 GBA1 (0.40) GBA1RAB9ASMN1; SMN2NPC1NFKB1
SCHEMBL24185335 0.72 GBA1 (0.40) GBA1RAB9ASMN1; SMN2NPC1NFKB1
SCHEMBL22510350 0.72 GBA1 (0.40) GBA1RAB9ASMN1; SMN2NPC1NFKB1
SCHEMBL19759439 0.72 SMN1; SMN2 (0.35) GBA1SMN1; SMN2KDM4EMAPTHTT
SCHEMBL17502182 0.71 HTT (0.41) GBA1RAB9ASMN1; SMN2KDM4EMAPT
SCHEMBL17427757 0.70 NOS3 (0.39) GBA1RAB9ASMN1; SMN2NPC1MAPK1
SCHEMBL40864 0.70 KDM4E (0.46) GBA1RAB9ASMN1; SMN2NPC1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084608-B2 2,2′ -bipyridine derivative having a reactive silyl group, its production method, and transition metal complex SHIN-ETSU CHEMICAL CO., LTD. (JP) 2011-12-27 US disclosed
US-20090299068-A1 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-12-03 US disclosed
EP-2128165-A1 2, 2´-bipyridine derivatives having reactive silyl group, production methods, transition metal complexes thereof Shin-Etsu Chemical Co., Ltd. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090299068-A1 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX CBR3, TST, HRH3 GBA1 4072/4885RAB9A 2346/4885SMN1; SMN2 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.